1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > Brexpiprazole (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Brexpiprazole (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • May 2014
  • -
  • GlobalData
  • -
  • 63 pages

Summary

Table of Contents

Brexpiprazole (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Summary

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly’s Cymbalta, and Otsuka/BMS’s Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda’s Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.

Otsuka Pharmaceutical initially developed Brexpiprazole but in 2011, the pharmaceutical company entered an agreement with Lundbeck for the co-development and co-commercialization of this product. The product is in Phase III development as an adjunctive therapy for MDD in the US and Europe, and is also being developed for the treatment of schizophrenia, anxiety disorders, dementia, post-traumatic stress disorder (PTSD), sleep disorders, and ADHD.

Scope

- Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Brexpiprazole including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Brexpiprazole for the top eight countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Major depressive disorder
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Brexpiprazole performance
- Obtain sales forecast for Brexpiprazole from 2013-2023 in the top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia)

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Major Depressive Disorder - Market Insights, Epidemiology and Market Forecast-2023

Major Depressive Disorder - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • March 2017
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Major Depressive Disorder - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...

Opportunity in Major Depressive Disorder Therapeutics in global market - 2017

Opportunity in Major Depressive Disorder Therapeutics in global market - 2017

  • $ 4500
  • Industry report
  • March 2017
  • by Feedback Business Consulting

This report provides insight into the current market scenario, structure and practices. In depth market scenario includes: - Current market size estimate - Revenues by players - Top 5 Companies - Market ...

Global Antidepressants Market - Segmented by Antidepressant Therapies, Depressive Disorders, and Geography (2017 - 2022)

Global Antidepressants Market - Segmented by Antidepressant Therapies, Depressive Disorders, and Geography (2017 - 2022)

  • $ 4250
  • Industry report
  • January 2017
  • by Mordor Intelligence LLP

The global antidepressants market is estimated to grow to approximately USD 13.4 billion by 2020, at a CAGR of 1.8%. Depression affects an estimated 121 million people worldwide and the antidepressant ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.